 Effectiveness low dose erythropoietin possible advantage high flux hemodialysis Recombinant human erythropoietin EPO stable out-patients end-stage renal disease ESRD priority basis times week patients underwent dialysis polysulfone hollow fiber dialyzers Mean time-averaged blood urea nitrogen BUN value mg/dl Kt/V urea initial dose EPO U/dialysis U/kg/dialysis maintenance U/dialysis mean time observation weeks patient EPO transfusion requirements target hematocrit patients hematocrits EPO increase /week dose EPO hematocrit response rate increase hematocrit small molecular weight solute removal Mean red blood cell survival days adjustments blood pressure BP medications dry weight BP data experiences recovery anemia ESRD effective dialysis bone marrow response EPO high flux hemodialysis